D377

Chong Kun Dang Pharmaceutical · Phase 3 active Small molecule

D377 is an investigational therapeutic agent in phase 3 development by Chong Kun Dang Pharmaceutical.

At a glance

Generic name	D377
Sponsor	Chong Kun Dang Pharmaceutical
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Limited publicly available information exists regarding the specific mechanism of action for D377. As a phase 3 candidate from Chong Kun Dang Pharmaceutical, it has progressed through early clinical development, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

D377 CI brief — competitive landscape report
D377 updates RSS · CI watch RSS
Chong Kun Dang Pharmaceutical portfolio CI